

**Novacyt S.A.**  
("Novacyt", the "Company" or the "Group")

**Strategy update and notice of investor presentation**

**Paris, France, and Manchester, UK - 22 October 2025** - Novacyt S.A. (Euronext Growth: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces it will issue an investor presentation today via the Investor Meet Company platform, detailing the Company's growth plan, providing FY25 outlook and will set out its strategic goals, as detailed below.

**FY25 outlook**

Novacyt expects to see a slight increase in H2 2025 revenues vs H1 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBench® Discover instrument. The Group expects to report an improvement in EBITDA loss for 2025 compared to the loss reported in FY24 of £9.1m which will be supported by an improved gross margin contribution. Cash outflow is also expected to improve in H2 2025 and will be lower than the H1 2025 cash outflow of £6.8m, largely as a result of completing the site consolidation and restructuring work.

**Organic financial goals**

Novacyt has set out and committed to the following three organic KPIs, clearly defined below:

- 1) To deliver double digit revenue growth year-on-year (from FY26)
- 2) To deliver a gross margin across the Group of over 60% each year (H1 FY25 66%)
- 3) To achieve EBITDA profitability based on the organic growth plans supported by the Company's balance sheet strength as soon as possible

**Growth strategy**

Following a period of restructuring, reducing the cost base and rightsizing the Group's operational footprint, the business is now derisked with a strong core business and foundations for growth. Novacyt has an established customer base in key markets and a robust commercialisation strategy to drive the business forward with the ability to rapidly pivot and leverage the Group's core capabilities to meet emerging market needs.

In 2024, the Company agreed to invest up to £2m per year from 2025-2027 to accelerate bringing new products to market. Novacyt continues to execute this strategy with product launches such as LightBench® Discover in July 2025, to support PacBio's labs using long read sequencers and the APAC focused NIPT solution which was launched in Q4 2025 to meet the changing needs of the APAC market. Through a mixed model strategy of licensing external technologies and building the Group's own products in-house, alongside strong partnerships and collaborations with blue chip partners, Novacyt has created a solid foundation from which it can deliver top line growth to support it reaching EBITDA profitability.

**Investor presentation**

The investor presentation will be issued on Wednesday 22 October at 7.00am BST and include presentations from Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, who will talk through the interim results for the six months ended 30 June, the organic financial targets set out by the Company above and how the Group is well positioned for growth. The presentation will also feature contributions from both Dr. Jo Mason, Chief Scientific Officer, and Maria Watters, Chief Commercial Officer, who will discuss the New Product Introduction strategy of the Group and Commercialisation.

Investors can sign up to Investor Meet Company for free and register [here](#).

The presentation will be made available on the Company's website here -  
<https://novacyt.com/investors/presentations/>

Shareholders and interested parties can sign up to receive the latest Company's announcements and updates by emailing: [novacyt@walbrookpr.com](mailto:novacyt@walbrookpr.com).

**Contacts**

**Novacyt SA**

Lyn Rees, Chief Executive Officer  
Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>

**Via Walbrook PR**

**SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

**Singer Capital Markets (Joint Broker)**

Tom Salvesen / Phil Davies / James Fischer / Samed Etherni

+44 (0) 20 7496 3000

**Allegra Finance (French Listing Sponsor)**  
Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

**Walbrook PR (Financial PR & IR)**  
Paul McManus / Lianne Applegarth  
Alice Woodings

+44 (0)20 7933 8780 or [novacyt@walbrookpr.com](mailto:novacyt@walbrookpr.com)

+44 (0)7980 541 893 / +44 (0)7584 391 303

+44 (0)7407 804 654

**About Novacyt Group ([www.novacyt.com](http://www.novacyt.com))**

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Clinical</b>        | Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas: <ul style="list-style-type: none"><li>Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests</li><li>Precision Medicine: DPYD genotyping assay</li><li>Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel</li></ul>                                        |
| <b>Instrumentation</b> | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: <ul style="list-style-type: none"><li>Ranger® Technology: automated DNA sample preparation and target enrichment technology</li><li>genesig q16 and q32 real-time quantitative PCR (qPCR) instruments</li></ul>                                                                                                        |
| <b>Research Only</b>   | <b>Use</b> Range of services for the life sciences industry: <ul style="list-style-type: none"><li>Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry</li><li>Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)</li></ul> |

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seq.com](mailto:ms@seq.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDPKDBNPBDDCKB